BioCorRx Inc
OTC:BICX
Intrinsic Value
BioCorRx, Inc. engages in the provision of alcoholism and opioid addiction treatment. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of BICX.
BioCorRx Inc's market capitalization is 15m USD.
BICX stock price is 1.76 USD.
BICX.
BICX. Open DCF Valuation
BICX. Open Relative Valuation
BICX.
BICX's Revenue has been growing by 10% per year for the last 3 years.
BICX's Revenue has grown by an exceptional 303% over the past 12 months.
BICX's ROE (Return on Equity) has significantly decreased in the last 3 years from 151% to 51%.
BICX's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -2 056% to 409%.
BICX has negative Operating Income for the last twelve months.
BICX has negative Net Income for the last twelve months.
BICX's ROE (Return on Equity) for the past 12 months is very high and is equal to 51%.
BICX's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 409%.
BICX has positive Gross Profit for the last twelve months.
BICX has negative Free Cash Flow for the last twelve months.
BICX has positive Net Debt. This means that the company has more debt (1m USD) than cash and short-term investments (197k USD).
BICX has very high three-year average ROE (Return on Equity): 108%. The company is very efficient at transforming stockholders' equity into net income.
BICX has negative three-year average ROIC (Return on Invested Capital): -1 002%. The company is not efficient at using invested capital to generate operating income.
BICX's short-term liabilties (6m USD) exceed its short-term assets (430k USD).
BICX's long-term liabilties (9m USD) exceed its long-term assets (757k USD).
BICX's D/E (Debt to Equity) is very low and is equal to -0.15.
BICX's Altman Z-Score is very low and is equal to -164.7.
Fundamental Analysis
BioCorRx Inc
Balance Sheet Decomposition
BioCorRx Inc
| Current Assets | 429.7k |
| Cash & Short-Term Investments | 197.3k |
| Receivables | 105.1k |
| Other Current Assets | 127.3k |
| Non-Current Assets | 327.1k |
| PP&E | 272.9k |
| Intangibles | 9.6k |
| Other Non-Current Assets | 44.5k |
| Current Liabilities | 5.7m |
| Accounts Payable | 2.3m |
| Accrued Liabilities | 2.2m |
| Short-Term Debt | 1.2m |
| Other Current Liabilities | 15.9k |
| Non-Current Liabilities | 3.6m |
| Long-Term Debt | 73.2k |
| Other Non-Current Liabilities | 3.6m |
Earnings Waterfall
BioCorRx Inc
|
Revenue
|
237.4k
USD
|
|
Cost of Revenue
|
-30.1k
USD
|
|
Gross Profit
|
207.3k
USD
|
|
Operating Expenses
|
-4.4m
USD
|
|
Operating Income
|
-4.2m
USD
|
|
Other Expenses
|
129.2k
USD
|
|
Net Income
|
-4m
USD
|
Free Cash Flow Analysis
BioCorRx Inc
BICX Profitability Score
Profitability Due Diligence
BioCorRx Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
BioCorRx Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
BICX Solvency Score
Solvency Due Diligence
BioCorRx Inc's solvency score is 28/100. The higher the solvency score, the more solvent the company is.
Score
BioCorRx Inc's solvency score is 28/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BICX Price Targets Summary
BioCorRx Inc
Ownership
BICX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
BICX Price
BioCorRx Inc
| Average Annual Return | 74.06% |
| Standard Deviation of Annual Returns | 225.77% |
| Max Drawdown | -89% |
| Market Capitalization | 15m USD |
| Shares Outstanding | 8 102 173 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
BioCorRx Inc
Country
Industry
Market Cap
Dividend Yield
Description
BioCorRx, Inc. engages in the provision of alcoholism and opioid addiction treatment. The company is headquartered in Anaheim, California. The company went IPO on 2010-08-31. The firm's BioCorRx Recovery Program is a non-addictive, medication-assisted treatment (MAT) program for substance abuse that includes peer recovery support. The UnCraveRx Weight Loss Management Program is a medically assisted weight management program that is combined with a virtual platform application. The company is also engaged in the research and development of sustained release naltrexone products for the treatment of addiction and other possible disorders. Its products include BICX101 and BICX104. Its lead candidate, BICX101, is a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism. The company is also developing an implantable naltrexone treatment, BICX104, a long-acting naltrexone implant that can last several months for the treatment of opioid dependence and alcohol use disorders. Its subsidiary is BioCorRx Pharmaceuticals, Inc.
You don't have any saved screeners yet
